Diazabicyclooctanes (DBOs): A potent new class of non-β-lactam β-lactamase inhibitors

Current Opinion in Microbiology

Volumn 14, Issue 5, 2011, Pages 550-555

  Coleman, Ken ^a  

^a Arietis Corp   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AVIBACTAM; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; CEFTAROLINE; CEFTAZIDIME; CILASTATIN; CILASTATIN PLUS IMIPENEM; CLAVULANIC ACID; DIAZABICYCLOOCTANE DERIVATIVE; IMIPENEM; MEROPENEM; METRONIDAZOLE; MK 7655; TAZOBACTAM; UNCLASSIFIED DRUG;

ACINETOBACTER BAUMANNII; AREA UNDER THE CURVE; DRUG HALF LIFE; ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; HISTORY OF MEDICINE; NONHUMAN; PSEUDOMONAS AERUGINOSA; REVIEW;

ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BACTERIA; BACTERIAL INFECTIONS; BETA-LACTAMASES; BETA-LACTAMS; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; ENZYME INHIBITORS; HUMANS;

NEGIBACTERIA;

EID: 81155162497     PISSN: 13695274     EISSN: 18790364     Source Type: Journal    
DOI: 10.1016/j.mib.2011.07.026     Document Type: Review

References (40)

1. Ambler R.P. The structure of β-lactamases. Philosophical Transactions of the Royal Society of London Series B, Biological Sciences 1980, 289:321-331.
2. Hall B.G., Barlow M. Revised Ambler classification of β-lactamases. Journal of Antimicrobial Chemotherapy 2005, 55:1050-1051.
3. Bush K., Jacoby G.A. Updated functional classification of β-lactamases. Antimicrobial Agents & Chemotherapy 2010, 54:969-976.
4. Philippon A., Labia R., Jacoby G. Extended-spectrum β-lactamases. Antimicrobial Agents & Chemotherapy 1989, 33:1131-1136.
5. Livermore D.M. Defining an extended-spectrum β-lactamase. Clinical Microbiology & Infection 2008, 14(Suppl. 1):3-10.
6. Walther-Rasmussen J., Høiby N. Class A carbapenemases. Journal of Antimicrobial Chemotherapy 2007, 60:470-482.
7. Bebrone C. Metallo-β-lactamases (classification, activity, genetic organization, structure, zinc coordination) and their superfamily. Biochemical Pharmacology 2007, 74:1686-1701.
8. Jacoby G.A. AmpC β-lactamases. Clinical Microbiology Reviews 2009, 22:161-182.
9. Walther-Rasmussen J., Høiby N. OXA-type carbapenemases. Journal of Antimicrobial Chemotherapy 2006, 57:373-383.
10. Poirel L., Naas T., Nordmann P. Diversity, epidemiology, and genetics of class D β-lactamases. Antimicrobial Agents & Chemotherapy 2010, 54:24-38.
11. Bush K. Alarming β-lactamase-mediated resistance in multidrug-resistant Enterobacteriaceae. Current Opinion in Microbiology 2010, 13:558-564.
12. Livermore D.M., Canton R., Gniadkowski M., Nordmann P., Rossolini G.M., Arlet G., Ayala J., Coque T.M., Kern-Zdanowicz I., Luzzaro F., et al. CTX-M: changing the face of ESBLs in Europe. Journal of Antimicrobial Chemotherapy 2007, 59:165-174.
13. Livermore D.M. Has the era of untreatable infections arrived?. Journal of Antimicrobial Chemotherapy 2009, 64(Suppl. 1):i29-i36.
14. Coates A.R., Halls G., Hu Y. Novel classes of antibiotics or more of the same?. British Journal of Pharmacology 2011, 163:184-194.
15. Bassetti M., Ginocchio F., Giacobbe D.R., Mikulska M. Development of antibiotics for Gram-negatives: where now?. Development 2011, 1:211-227.
16. Bush K., Macielag M.J. New β-lactam antibiotics and β-lactamase inhibitors. Expert Opinion on Therapeutic Patents 2010, 20:1277-1293.
17. Drawz S.M., Bonomo R.A. Three decades of β-lactamase inhibitors. Clinical Microbiology Reviews 2010, 23:160-201.
18. Bebrone C., Lassaux P., Vercheval L., Sohier J.S., Jehaes A., Sauvage E., Galleni M. Current challenges in antimicrobial chemotherapy: focus on β-lactamase inhibition. Drugs 2010, 70:651-679.
19. Stachyra T., Péchereau M.C., Bruneau J.M., Claudon M., Frère J.M., Miossec C., Coleman K., Black M.T. Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-β-lactam β-lactamase inhibitor. Antimicrobial Agents & Chemotherapy 2010, 54:5132-5138.
20. Docquier J.D., Stachyra T., Benvenuti M., Rossolini G.M., Mangani S., Pechereau M.C., Bruneau J.M., Claudon M., Barbosa F., Miossec C., Black M.T. High resolution crystal structure of CTX-M-15 in complex with the new β-lactamase inhibitor NXL104. 49th International Congress of Antimicrobial Agents & Chemotherapy 2009, C1-C1098.
21. Bonnefoy A., Dupuis-Hamelin C., Steier V., Delachaume C., Seys C., Stachyra T., Fairley M., Guitton M., Lampilas M. In vitro activity of AVE1330A, an innovative broad-spectrum non-β-lactam β-lactamase inhibitor. Journal of Antimicrobial Chemotherapy 2004, 54:410-417.
22. Young K., Raghoobar S.L., Hairston N.N., Painter R.E., Racine F., Dorso K.L., Park Y.-W., Ogawa A.M., Wisniewski D., Hermes J., Blizzard T.A., et al. In vitro activity of the class A and C β-lactamase inhibitor MK-7655. 50th International Congress of Antimicrobial Agents & Chemotherapy 2010, F1-F2139.
23. Miossec C., Claudon M., Patel D., Levasseur P., Hodgson J.E., Black M.T. The β-lactamase inhibitor NXL104 does not induce AmpC β-lactamase expression in Enterobacter cloacae. 46th International Congress of Antimicrobial Agents & Chemotherapy 2006, F-128.
24. Queenan A.M., Bush K. Carbapenemases: the versatile β-lactamases. Clinical Microbiology Reviews 2007, 20:440-458.
25. Livermore D.M., Mushtaq S., Warner M., Zhang J., Maharjan S., Doumith M., Woodford N. Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae. Antimicrobial Agents & Chemotherapy 2011, 55:390-394.
26. Livermore D.M., Mushtaq S., Warner M., Miossec C., Woodford N. NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum β-lactamases and carbapenemases. Journal of Antimicrobial Chemotherapy 2008, 62:1053-1056.
27. Lagacé-Wiens P.R.S., Tailor F., Simner P., Nichol K., Hoban D., Zhanel G.G. Activity of NXL104 in combination with β-lactams against genetically characterized class A and class C β-lactamase-producing Escherichia coli and Klebsiella pneumoniae. 50th International Congress of Antimicrobial Agents & Chemotherapy 2010, Poster E-807.
28. Mushtaq S., Warner M., Livermore D.M. In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters. Journal of Antimicrobial Chemotherapy 2010, 65:2376-2381.
29. Walkty A., DeCorby M., Lagacé-Wiens P.R., Karlowsky J.A., Hoban D.J., Zhanel G.G. In vitro activity of ceftazidime combined with NXL104 versus Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals: (CANWARD 2009 study). Antimicrobial Agents and Chemotherapy 2011, 55:2992-2994.
30. Citron D.M., Tyrrell K.L., Merriam V., Goldstein E.J. In vitro activity of ceftazidime-NXL104 against 396 strains of β-lactamase producing anaerobes. Antimicrobial Agents and Chemotherapy 2011, 55:3616-3620.
31. Merdjan H., Tarral A., Girard A.M., Levasseur P., Lowther J., Miossec C., Chassard D., Rangaraju M. Safety, single dose pharmacokinetics, and pharmacodynamics of β-lactamase inhibitor NXL104 in healthy young male adults. 47th International Congress of Antimicrobial Agents & Chemotherapy 2007, Poster #A-809.
32. Tarral A., Lipka J., Gyaw S., Pencheva P., Merdjan H., Heber W., Cheung V., Garner R., Sable C. Effect of age and gender on the pharmacokinetics (PK) and safety of NXL104 in healthy subjects (Protocol NXL104/1004). 49th International Congress of Antimicrobial Agents & Chemotherapy 2009, Poster A1-007.
33. Vazquez J.A., González-Patzán L.D., Lipka J., Sable C. Efficacy, safety and tolerability of ceftazidime avibactam (ceftazidime/NXL104) versus imipenem cilastatin in the treatment of complicated urinary tract infections in hospitalised adults. 21st European Congress of Clinical Microbiology & Infectious Diseases/27th International Congress of Chemotherapy 2011, Poster P1533.
34. Lucasti C., Popescu I., Ramesh M., Lipka J., Sable C. Efficacy and safety of ceftazidime avibactam (ceftazidime/NXL104) plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalised adults. 21st European Congress of Clinical Microbiology & Infectious Diseases/27th International Congress of Chemotherapy 2011, Poster P1532.
35. Sader H.S., Castanheira M., Farrell D.J., Jones R.N. Antimicrobial spectrum and potency of ceftaroline combined with NXL104 when tested against Enterobacteriaceae collected from USA hospitals. 50th International Congress of Antimicrobial Agents & Chemotherapy 2010, Poster E-821.
36. Sader H.S., Williams G., Critchley I., Jones R.N. Spectrum and activity of ceftaroline combined with NXL104 tested against a challenge collection of pathogens with well characterized resistance. 49th International Congress of Antimicrobial Agents & Chemotherapy 2009, Poster F1-1492.
37. Wiskirchen D.E., Crandon J.L., Furtado G.H., Williams G., Nicolau D.P. In vivo efficacy of a human-simulated regimen of ceftaroline combined with NXL104 against ESBL- producing and non-ESBL-producing Enterobacteriaceae. Antimicrobial Agents and Chemotherapy 2011, 55:3220-3225.
38. Butterton J.R., Jumes P., Calder N., Rizk M.L., Nefliu M., Sun P., Schwartz M., Mangini E., Warrington S., Stoch A., Wagner J.A. A phase 1 study evaluating the safety, tolerability, and pharmacokinetics of an intravenous β-lactamase inhibitor in healthy male volunteers. 50th International Congress of Antimicrobial Agents & Chemotherapy 2010, Slide Presentation F1-1967.
39. Karlowski J.A., DeCorby M., Lagace-Wiens P., Adams H., Nichol K., Hoban D.J., Zhanel G.G. In vitro activity of ceftaroline against 5375 pathogens obtained from patients in Canadian hospitals: CANWARD 2009. 50th International Congress of Antimicrobial Agents & Chemotherapy 2010, Poster E-815.
40. Lagacé-Wiens P., Simner P., Tailor F., DeCorby M., Karlowsky J., Hoban D., Zhanel G.G. Activity of ceftazidime/NXL104 versus CAZ alone and other comparators against 2399 Gram-negative bacilli-results from CANWARD 2009. 50th International Congress of Antimicrobial Agents & Chemotherapy 2010, Poster E-806.